Why does administering a drug metabolized via hepatic glucuronidation to a patient with Gilbert's syndrome potentially increase drug toxicity?

💡 Explanation

Gilbert's syndrome causes reduced activity of the UDP-glucuronosyltransferase 1A1 (UGT1A1) enzyme, which is responsible for bilirubin conjugation and also the glucuronidation of many drugs. Because glucuronidation is impaired, the drug's half-life increases, therefore drug toxicity can increase, rather than blood flow changes reducing drug effect.

• If an adjuvant is omitted from a vaccine administered to a patient, which consequence follows regarding B-cell response?
• If a burn injury compromises the epidermal skin barrier function, which consequence is most likely regarding systemic fluid balance?
• Why does chronic stress disrupt the endocrine system's hormone balance?
• A patient reports difficulty learning new motor skills after a stroke impacted their hippocampus; which sleep-related effect explains this deficit?
• Why does propofol anesthesia cause a rapid loss of consciousness after intravenous administration?
• What causes reduced erythropoietin production when kidney filtration declines?